Compass Therapeutics, Inc. (CMPX) Financials
Annual revenue, profitability and per-share results for Compass Therapeutics, Inc., as reported in SEC filings.
Revenue • FY2025
$0
▼ 100.0%YoY
Net income • FY2025
-$66.49M
▼ 34.7%YoY
Compass Therapeutics, Inc. took this name in a reverse merger on Jun 8, 2020
The reports Olivia Ventures, Inc. filed before the merger describe a different business, so they aren’t shown.
Compass Therapeutics, Inc.’s first annual report since the merger will restate those years.
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $0 | -$66.49M | — | — | -$49.17M | — | -100.0% |
| FY2024 | $850K | -$49.38M | — | — | -$44.9M | -6661.8% | — |
| FY2023 | $0 | -$42.49M | — | — | -$40.65M | — | — |
| FY2022 | $0 | -$39.23M | — | — | -$34.34M | — | — |
Figures as reported in Compass Therapeutics, Inc.'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a CMPX filing.
Get an email when CMPX files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.